Otros idiomas Johnson & Johnson Santiago S.E.

Acciones

JNJ

US4781601046

Precio de cierre Santiago S.E. Otros sitios de cotización 00:00:00 28/06/2024			Varia. Cinco días.	Varia. 1 de enero.
148,3 ^USD	-.--%		-.--%	-6,76 %

08:00	Bolsa de Madrid: Un nuevo semestre, un nuevo estado de ánimo
28/06	Johnson & Johnson informa de resultados "positivos" en un ensayo de fase tardía sobre miastenia grave	MT

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Momentum Picks T3 2024 : 5 actions pour l'été	09:43
En Direct des Marchés : Thales, Airbus, Sanofi, Stellantis, Atos, Valneva, Boeing...	08:24
Nouveau semestre, nouvel état d'esprit	08:12
Borsa di Italia: Un nuovo semestre, un nuovo umore	08:00
Johnson & Johnson : CHMP adopts positive opinion for BALVERSA® (erdafitinib) for the treatment of adult patients	28/06
Johnson & Johnson Reports 'Positive' Results in Late-Stage Myasthenia Gravis Trial	28/06
J&J Unit's Rybrevant Combo Gets EU Approval	28/06
Nipocalimab pivotal Phase 3 trial demonstrates longest sustained disease control in FcRn class for broadest population of myasthenia gravis patients	28/06
Johnson & Johnson Announces Positive Results from the Nipocalimab Phase 3 Vivacity-MG3 Study	28/06
Johnson & Johnson : CHMP adopts positive opinion for BALVERSA® (erdafitinib) for the treatment of adult patients with unresectable or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations	28/06
Johnson & Johnson's Balversa Gets EU Panel Recommendation for Urothelial Carcinoma	28/06
Dealmakers optimistic on global M&A prospects despite sluggish growth	28/06
Lawyers for Johnson & Johnson’s Ovarian Cancer Victims React to SCOTUS Decision in Purdue	28/06
A New Wave Of ERISA Class Actions?: Some Employer/Fiduciary Implications Of Lewandowski V. Johnson & Johnson (Podcast)	27/06
US FDA declines to approve Merck-Daiichi's 'guided missile' cancer drug	27/06
Johnson & Johnson Reaches 50 Million Children Through Sight For Kids Program	25/06
US Supreme Court gives pharma companies a chance to thwart terrorism-funding lawsuit	24/06
J&J : 50M d'élèves aidés via le programme 'Sight for Kids'	24/06
Johnson & Johnson completes acquisition of Proteologix, Inc.	24/06
Sector Update: Health Care Stocks Edge Up in Afternoon Trading	21/06

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Titulares

Joseph Wolk, Director Financiero de J&J: Fin de la patente de su medicamento estrella

23 de enero 2024 a las 18:30